Dihydropyrimidine Dehydrogenase Expression in Breast Cancer
Author Information
Author(s): Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y, Morishita Y
Primary Institution: Gunma University Faculty of Medicine
Hypothesis
Is dihydropyrimidine dehydrogenase expression a prognostic marker in breast cancer?
Conclusion
Dihydropyrimidine dehydrogenase may be a prognostic factor for breast cancer patients treated with 5-fluorouracil.
Supporting Evidence
- 50% of patients showed positive immunostaining for DPD.
- DPD-positive patients had poorer disease-free survival compared to DPD-negative patients.
- DPD and lymph node status were independent prognostic factors for disease-free survival.
Takeaway
This study looked at a protein called dihydropyrimidine dehydrogenase in breast cancer to see if it could help predict how well patients would do after treatment.
Methodology
Immunohistochemical study of DPD expression in breast cancer tissues from 119 women.
Limitations
No conclusions could be drawn about DPD status in patients not treated with 5-FU due to small sample size.
Participant Demographics
119 women with breast cancer, ages 30 to 85, median age 51.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website